China Digital Therapeutics Industry Benchmark Event: VB100·2021 China Digital Therapeutics Conference Gathers 100+ Leading Companies and 40 Industry Leaders
[VB100·2021 China Digital Therapeutics Conference] Postponement Notice
Recently, the COVID-19 epidemic in China has spread to multiple provinces and municipalities, with a significant increase in medium- and high-risk areas across the country, making the epidemic prevention and control situation severe and complex. To further safeguard the health of conference attendees and effectively cooperate with the government in epidemic prevention and control efforts, the event originally scheduled to be held in Binjiang District, Hangzhou, from December 7 to December 8,VB100·2021 China Digital Therapeutics ConferenceThe event is postponed; the specific date is to be determined and will be announced separately in accordance with government requirements.
We sincerely apologize for any inconvenience caused by the postponement of this conference. We kindly request all attendees to adjust their travel and work schedules accordingly. Thank you for your continued understanding and support!
"Throughout history, the paths people have taken and those they have not have all become the paths we must now tread."
Among the emerging innovative healthcare subsectors in 2021, “Digital Therapeutics” undoubtedly ranks at the top. Digital therapeutics fully unleash the immense potential of the internet and advanced technologies within the healthcare industry, while the full-scale outbreak of the pandemic in 2020 served as a catalyst accelerating the development of digital therapeutics. In the post-pandemic era, digital therapeutics will actively influence people’s daily healthy lives in the foreseeable future.
Innovation Entails Risk, TodayWhat are the development trends in the digital therapeutics industry ecosystem?How to BetterIntegrating Digital Therapeutics with Various Diseases，How Digital Therapeutics Products Can Achieve Commercial Implementation, and How to Deconstruct the Challenges Facing the Development of the Digital Therapeutics Industryhas become a direction of concern and reflection for the industry. Against this backdrop, byHangzhou National High-Tech Industrial Development Zone Administrative Committee, People's Government of Binjiang District, Hangzhou CityGuidance、VCBeat, VB100, VCBeat Research Institute, TigermedHosted byVB100 · 2021 China Digital Therapeutics ConferenceIt will be held in Binjiang District, Hangzhou from December 7 to December 8, 2021.
VB100·2021 China Digital Therapeutics Conference is the Chinese digital therapeutics industryLargest Scale, Most Up-to-Date Information, High-Quality EnterprisesMost,Representing the Highest Level of Development in China's Digital Therapeutics Industryannual conference. Through this annual congress, we aim to provide elite professionals from China’s digital therapeutics and digital health sectors—including industry leaders, technical experts, clinicians, and investment institutions—with opportunities for observation, learning, and direct exchange. The event will serve as a platform for sharing experiences in innovation, entrepreneurship, and product design, while connecting peers around key challenges, solutions, and the commercialization models of innovative enterprises. Additionally, it will explore how to integrate digital therapeutics into clinical practice and patient disease management options.
(Click to register:http://hdxu.cn/jCmLx）
Digital therapeutics (DTx) are currently in an early stage of innovation but hold significant market potential. According to incomplete statistics from the VCBeat Orange Database, total disclosed financing in the global digital health sector exceeded USD 2.048 billion (approximately RMB 13.206 billion) in September 2021, with four DTx deals alone surpassing USD 100 million in May. Digital therapeutics can effectively integrate the healthcare value chain, providing deep empowerment to upstream and downstream industries. Meanwhile, advanced technologies such as artificial intelligence, the Internet of Things (IoT), and big data are rapidly penetrating the healthcare sector, reshaping modern diagnostic and treatment paradigms. A growing number of companies are entering this field, driven by mergers and acquisitions of DTx startups and venture capital support, which has propelled digital therapeutics into the spotlight as an innovative healthcare model. Additionally, prescription of DTx by healthcare professionals and patient involvement in research and development have become notable highlights of the industry. As a fusion of innovative technology and clinical practice, the DTx sector urgently needs to return to rationality amid emerging challenges related to technological barriers, commercial implementation, and market competition.
2021 China Digital Therapeutics ConferenceThe Premier Annual Summit Showcasing the Highest Level of Development in China’s Digital Therapeutics Industry, we aim to address the following issues:
What Disagreements/Gaps Exist in Digital Therapeutics Themselves? How Can They Be Resolved?
What Are the Core Technologies of Digital Therapeutics?
How to Prove the Efficacy and Benefits of Digital Therapeutics?
Business Models and Clinical Validation Methods for Digital Therapeutics?
How Can the Introduction of Digital Therapeutics into Healthcare Promote Equity?
......
Stay Ahead of Trends：One high-end digital therapeutics summit + one global closed-door roadshow + one closed-door seminar, directly addressing critical pain points
This event willFromTrend Analysis, Brand Empowerment, Partnership MatchmakingFrom Three Key Dimensions: A Comprehensive Analysis of the Development Trends in the Digital Therapeutics Industry Ecosystem, Exploring the Medical Value and Commercial Pathways Across Various Sub-Scenarios Through Multi-Level, Multidimensional Discussion.
Top-Tier Guests：Led by an academician, over 40 core experts in the field of digital therapeutics from both China and abroad attended, connecting more than 100 innovative digital therapeutics companies.
We plan to invite 1–2 academicians, 3–5 leaders and experts from national regulatory bodies such as the Center for Medical Device Evaluation (CMDE), the National Health Commission, and the National Healthcare Security Administration, as well as 5–10 executives responsible for management at clinical medical institutions. The event will bring together five Fortune Global 500 companies and over 100 other participants, including pharmaceutical, medical device, smart equipment, insurance payment, digital therapeutics, and internet healthcare platform companies, as well as investment firms, from both China and overseas.
Highest Level：Release of China’s First Report on Exploratory Practices in the Digital Therapeutics Industry
As China’s first compendium of exemplary cases and corporate growth trajectories in the digital therapeutics industry, this report adheres to relevant principles while conducting an in-depth analysis and summary of the developmental experiences gained from localizing innovative digital therapeutics projects in China. By exploring implementation pathways, identifying case studies, and establishing benchmark models, the report aims to provide positive guidance, encourage innovation, and openly address controversies, thereby offering targeted recommendations for industry improvement.
Industrial Agglomeration：Establishing China’s First Digital Therapeutics Industrial Park
The conference features diverse activities to facilitate partnership matchmaking and cultivate industry landmarks. Over the next decade, a digital healthcare industry valued at over RMB 10 trillion, characterized primarily by data, is poised to emerge. Digital therapeutics are expected to become a key pillar within the healthcare industry chain, presenting new opportunities for aggregation and restructuring in China’s RMB 10-trillion-level digital healthcare sector.
VB100·2021 China Digital Therapeutics Conference | |||
Date | Project | Highlights | |
12.7 | Afternoon | Digital Therapeutics Policy and Industry Closed-Door Roadshow | Proposed Invitation of Leaders from Government Investment Promotion Departments and Regulatory Authorities for Direct Dialogue Among Government, Industry, and Capital |
12.8 | Morning | VB100·2021 China Digital Therapeutics Conference | 1, Regulatory, Clinical, Financial, Pharmaceutical Companies, Payers, and Industry: Interpretation from Six Major Perspectives 2. Release China's First Report on the Exploration and Practice of the Digital Therapeutics Industry 3. Establish China’s First Digital Therapeutics Industrial Park |
Afternoon | |||
Digital Therapeutics Standards Workshop | Proposed Invitation to the Hangzhou Healthcare Security Standardization Office for Participation | ||
(Digital Therapeutics Conference Forum)
We hope,VB100 · 2021 China Digital Therapeutics ConferenceCapable of meeting the growth demands of innovative digital therapeutics companies; to this end, focusing on the fullShowcasing the Industrial Innovation EcosystemandFully Promote Industry Exchange and InteractionTwo core objectives, fromTrend Analysis, Brand Empowerment, Partnership MatchmakingComprehensive Analysis of the Development Trends in the Digital Therapeutics Industry Ecosystem from Three Major Dimensions: Exploring the Medical Value and Commercial Pathways in Various Sub-Scenarios through Multi-Level, Multidimensional Discussion.
Furthermore, this conference coversIndustry-Academia-Research-MedicineCapitalFive Major Ecosystems, comprehensively showcasing China’s innovative digital therapeutics landscape and fostering robust cross-industry exchange and interaction. Meanwhile, the conference will feature a diverse range of networking activities designed to meet corporate needs, provide access to cutting-edge insights, and facilitate connections with top-tier resources.
Time: December 7–8, 2021
Location: Hangzhou Binjiang District
Organizational Structure:
Guiding Organizations:Hangzhou National High-Tech Industrial Development Zone Administrative Committee, People's Government of Binjiang District, Hangzhou City
Organizers: VCBeat, VB100, VCBeat Research Institute, Tigermed
Co-organized by:Hangzhou Binjiang District Bureau of Economy and Information Technology, Zhilan Health
Partners: Legend Capital, BV Baidu Ventures, Honghui Capital, Weilai Zhuoshi, Changling Capital, Yuanyi Capital,Probe Capital, Jianhai Technology
"Coming together is fate; walking together is happiness. May new and old friends on the path of digital therapeutics innovation gather together by the end of 2021."
Registration for the conference is now open. In response to epidemic prevention and control measures, attendance at this conference is limited to400slots. This event will adopt a free review system, and everyone is welcome to register enthusiastically. Detailed information will be gradually updated in the following period, with the framework expected to be publicly released in early November. Stay tuned.
(Scan the QR code to register)
Conference Partnership Application:http://nxw.so/6tCUd
Note: The epidemic prevention and control situation is severe and complex. To effectively cooperate with the government in epidemic prevention and control efforts, the conference has been postponed,The specific date is to be determined., will be announced separately in accordance with government requirements.